A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Selinexor (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- Acronyms SELECT
- 06 Apr 2018 Status changed from not yet recruiting to recruiting.
- 12 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.
- 17 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Jan 2018.